07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Caliber Biotherapeutics, Mapp Biopharmaceutical, U.S. Department of Health and Human Services infectious news

HHS said it is in talks with biomanufacturing company Caliber to produce Mapp's ZMapp Ebola treatment. HHS said it wants to boost ZMapp production further and noted Caliber has expertise in tobacco plant-based vaccine and...
03:06 , Oct 3, 2014 |  BC Extra  |  Company News

HHS seeks to boost ZMapp production

HHS said it is in talks with biomanufacturing company Caliber Biotherapeutics LLC (Bryan, Texas) to produce the experimental Ebola drug ZMapp . Mapp Biopharmaceutical Inc. (San Diego, Calif.) produces the combination of 3 mAbs targeting...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Caliber Biotherapeutics, iBio deal

The partners designated a fusion protein for cancer as the first product target to advance under a 2013 deal granting Caliber a non-exclusive license to use iBio's iBioLaunch plant-based vaccine and therapeutic protein manufacturing platform...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Caliber Biotherapeutics, ImmunGene preclinical data

In mouse xenograft models of non-Hodgkin's lymphoma (NHL), IGN002 achieved superior efficacy vs. rituximab and control fusion protein (p=0.002 and p<0.0001, respectively). In vitro, IGN002 showed stronger growth inhibition than rituximab in multiple lymphoma lines....
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Caliber Biotherapeutics, ImmunGene, LLS cancer news

The society provided about $6 million in funds to Valor Biotherapeutics LLC, a JV between ImmunGene and Caliber, to develop IGN002 to treat non-Hodgkin's lymphoma (NHL) in patients who are resistant to standard therapy with...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Company News

Caliber Biotherapeutics, iBio deal

iBio granted Caliber a non-exclusive license to use iBio's iBioLaunch plant-based vaccine and therapeutic protein manufacturing platform to develop and commercialize biopharmaceuticals against targets provided by Caliber. Caliber will also provide its plant-based manufacturing technology....
07:00 , Nov 1, 2012 |  BC Innovations  |  Strategy

Mess with Texas

The public spat between the scientific board and management of the Cancer Prevention & Research Institute of Texas is a case study in how commercial and scientific interests can clash when the two sides are...